Madrigal (MDGL)
NASDAQ:MDGL
Want to see MDGL full AI Analyst Report?
MDGL Stock Chart & Stats
$532.02
-$1.78(-0.55%)
At close: 4:00 PM EST
$532.02
-$1.78(-0.55%)
Day’s Range― - ―
52-Week Range$268.69 - $615.00
Previous CloseN/A
Volume47.78K
Average Volume (3M)279.89K
Market Cap
$10.44B
Enterprise Value$11.58B
Total Cash (Recent Filing)$817.93M
Total Debt (Recent Filing)$347.31M
Price to Earnings (P/E)―
Beta0.28
Next Earnings
Aug 11, 2026EPS Estimate
-2.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-12.80
Shares Outstanding23,055,658
10 Day Avg. Volume268,785
30 Day Avg. Volume279,890
Financial Highlights & Ratios
PEG Ratio1.10
Price to Book (P/B)21.68
Price to Sales (P/S)13.63
P/FCF Ratio-68.75
Enterprise Value/Market Cap1.11
Enterprise Value/Revenue10.23
Enterprise Value/Gross Profit10.99
Enterprise Value/Ebitda-40.26
Forecast
1Y Price Target
$649.82Price Target Upside22.14% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-6.55
Revenue Forecast (FY)$1.50B
Bulls Say, Bears Say
Bulls Say
Strong Revenue Growth And ScaleSustained blockbuster sales demonstrate durable commercial traction and physician adoption, providing a scalable revenue base to fund operations and pipeline investment. Continued patient additions and steep YoY growth support mid-term cash generation potential once margins offset operating spend.
Very High Gross MarginsExtremely strong product-level margins imply attractive unit economics and pricing power for Rezdiffra. High gross margins create structural capacity to absorb SG&A and R&D as the business scales, improving odds of eventual operating leverage and durable profitability once sales volume stabilizes.
Pipeline Expansion And Strategic In‑licenseA diversified pipeline and the ARO‑PNPLA3 siRNA in‑license reduce single-product concentration risk and extend long-term growth optionality. Clinical-stage, genetically targeted data support potential new indications and revenues beyond the current U.S. launch, strengthening strategic resilience.
Bears Say
Negative Operating And Free Cash FlowPersistent cash burn is a structural constraint on financial flexibility, necessitating financing or resource reallocation until operating cash flow turns positive. Even with sizeable cash on hand, continued negative OCF raises execution risk and dependency on successful commercialization and margin conversion.
Elevated Operating Expenses; Near‑term UnprofitabilityHigh SG&A and R&D (including BD and DTC investments) create a multi-quarter profit hurdle. Until revenue growth sustainably outpaces operating expense expansion, profitability will remain elusive, pressuring cash flow and constraining reinvestment flexibility over the medium term.
High Gross‑to‑net Discounts Weighing On Realized RevenueSubstantial gross‑to‑net allowances materially reduce realized revenue and cap achievable net margins, reflecting durable payer and rebate dynamics. This structural headwind limits cash conversion from sales and magnifies the importance of scale and pricing strategies to reach sustainable profitability.
Madrigal Pharmaceuticals News
MDGL FAQ
What was Madrigal’s price range in the past 12 months?
Madrigal lowest stock price was $268.69 and its highest was $615.00 in the past 12 months.
What is Madrigal’s market cap?
Madrigal’s market cap is $10.44B.
When is Madrigal’s upcoming earnings report date?
Madrigal’s upcoming earnings report date is Aug 11, 2026 which is in 69 days.
How were Madrigal’s earnings last quarter?
Madrigal released its earnings results on May 06, 2026. The company reported -$3.25 earnings per share for the quarter, beating the consensus estimate of -$4.23 by $0.98.
Is Madrigal overvalued?
According to Wall Street analysts Madrigal’s price is currently Undervalued.
Does Madrigal pay dividends?
Madrigal does not currently pay dividends.
What is Madrigal’s EPS estimate?
Madrigal’s EPS estimate is -2.39.
How many shares outstanding does Madrigal have?
Madrigal has 23,055,658 shares outstanding.
What happened to Madrigal’s price movement after its last earnings report?
Madrigal reported an EPS of -$3.25 in its last earnings report, beating expectations of -$4.23. Following the earnings report the stock price went up 7.415%.
Which hedge fund is a major shareholder of Madrigal?
Currently, no hedge funds are holding shares in MDGL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Madrigal Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$649.82 (22.14% Upside)
$649.82 (22.14% Upside)
Blogger Sentiment
Bullish
MDGL Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 336.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 1.1%
Last 30 Days ▼ 1.1%
News Sentiment
Bullish
Bullish news 79%
Bearish news 33%
Bearish news 33%
Technicals
SMA
Positive
20 days / 200 days
Momentum
66.08%
12-Months-Change
Fundamentals
Return on Equity
-50.15%
Trailing 12-Months
Asset Growth
23.15%
Trailing 12-Months
Company Description
Madrigal
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.
MDGL Company Deck
MDGL Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a strongly positive commercial and scientific momentum: Rezdiffra has achieved blockbuster status with rapid patient growth, a materially expanding addressable market, and an increasingly diverse pipeline (including a promising siRNA asset). These positives are balanced by elevated operating expenses, one‑time business development costs, a material gross‑to‑net discount, and near‑term non‑profitability with cash modestly reduced by strategic uses. Management emphasized durable long‑term opportunity, upcoming outcomes milestones (2027–2028), and disciplined, data‑driven pipeline advancement.View all MDGL earnings summariesMDGL Stock 12 Month Forecast
Average Price Target
$649.82
▲(22.14% Upside)
Technical Analysis
Exelixis
―
Ionis Pharmaceuticals
―
Ascendis Pharma
―
BridgeBio Pharma
―
Roivant Sciences
―
Ownership Overview
17.99% Insiders
23.20% Mutual Funds
7.53% Other Institutional Investors
38.22% Public Companies and
Individual Investors